See supra note 1
References Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
The answer from the data is clear: do not
Some GLP-1 medications are used for diabetes management, while others are approved specifically for chronic weight management
On behalf of the VERTIS CV Investigators, Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, et al
Research Compound Summary Compound: Retatrutide CAS Number: 2381089-83-2 Molecular Formula: C205H320N56O63S2 Purity: 99.71% (HPLC-UV verified) Third-Party Testing: Testides Analytical (independent lab, Toronto) COA Download: View Full COA (PDF) Report: DBAV-RETA-10-062726 Source: Canadian manufactured Shipping: Same-day from our BC facility Retatrutide peptide Canada: a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously